Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project)

Infection

Volumn 41, Issue 3, 2013, Pages 645-653

  Montagna, M T ^a   Caggiano, G ^a   Lovero, G ^a   De Giglio, O ^a   Coretti, C ^a   Cuna, T ^a   Iatta, R ^a   Giglio, M ^a   Dalfino, L ^a   Bruno, F ^a   Puntillo, F ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Candidemia; Drug susceptibility; Intensive care unit; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; POSACONAZOLE; PREDNISONE; PYRROLE DERIVATIVE; VORICONAZOLE;

ADULT; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTIFICIAL VENTILATION; ASPERGILLUS FUMIGATUS; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; FEMALE; FUNGAL COLONIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PICHIA GUILLIERMONDII; REVIEW; SYSTEMIC MYCOSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; PREVALENCE; SCEDOSPORIUM;

EID: 84878823678     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0432-0     Document Type: Review

References (41)

1. Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008;34:292-9.
2. Dimopoulos G, Ntziora F, Rachiotis G, et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106:523-9.
3. Glöckner A, Karthaus M. Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. Mycoses. 2011;54:420-33.
4. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206-13.
5. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612-8.
6. Caggiano G, Iatta R, Laneve A, et al. Observational study on candidaemia at a university hospital in southern Italy from 1998 to 2004. Mycoses. 2008;51:123-8.
7. Horasan ES, Ersöz G, Göksu M, et al. Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 2010;170:263-8.
8. Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011;54:154-61.
9. Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33:1679-81.
10. Russo A, Falcone M, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. J Chemother. 2011;23:290-4.
11. Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses. 2012;55:73-9.
12. Montagna MT, Lovero G, De Giglio O, et al. Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). J Prev Med Hyg. 2010;51:125-30.
13. Montagna MT, De Giglio O, Napoli C, et al. Invasive fungal infections in patients with hematologic malignancies (AURORA project): lights and shadows during 18-months surveillance. Int J Mol Sci. 2012;13:774-87.
14. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-8.
15. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
16. de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 3rd ed. The Netherlands: Centraalbureau voor Schimmelcultures (CBS); 2009.
17. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 2nd ed. CLSI document M38-A2. Wayne: CLSI; 2008.
18. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd ed. CLSI document M27-A3. Wayne: CLSI; 2008.
19. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3-13.
20. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70:330-43.
21. Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170-7.
22. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48:3251-7.
23. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150-4.
24. Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855-9.
25. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644-50.
26. Chalmers CM, Bal AM. Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth. 2011;106:827-31.
27. Jordà-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses. 2007;50:302-10.
28. Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.
29. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1-45.
30. Nucci M, Queiroz-Telles F, Tobón AM, et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis. 2010;51:561-70.
31. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606-25.
32. Negri M, Silva S, Henriques M, Oliveira R. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur J Clin Microbiol Infect Dis. 2012;31:1399-412.
33. Bassetti M, Ansaldi F, Nicolini L, et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009;64:625-9.
34. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005;49:4555-60.
35. Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents. 2011;38:65-9.
36. Tortorano AM, Prigitano A, Dho G, et al. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389-93.
37. Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48:1270-5.
38. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.
39. Vandewoude KH, Blot SI, Benoit D, et al. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269-76.
40. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782-800.
41. Maris C, Martin B, Creteur J, et al. Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch. 2007;450:329-33.